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ABSTRACT
Introduction: High-grade glioma (HGG) is a rapidly
progressive and debilitating disease. Primary carers
experience significant levels of distress which impacts
on their experience of caregiving, the quality of care
received and the community in terms of the increased
reliance on healthcare due to the potential development
of complicated grief. This paper describes the protocol
for testing the efficacy and feasibility of an intervention
for primary carers of patients with HGG in order to
improve preparedness to care and reduce carer distress.
Methods: Randomised controlled trial. The target
population is carers of patients with HGG who are
undergoing combined chemoradiotherapy. The
intervention consists of 4 components: (1) initial
telephone assessment of unmet needs of the carer,
(2) tailoring of a personalised resource folder,
(3) home visit, (4) ongoing monthly telephone contact
and support for 12 months. The control arm will
receive usual care.
Primary hypothesis: This intervention will improve
preparedness for caring and reduce carer psychological
distress.
Secondary hypothesis: This intervention will reduce
carer unmet needs. The longer term aim of the
intervention is to reduce patient healthcare resource
utilisation and, by doing so, reduce costs. Assessments
will be obtained at baseline, 8 weeks post intervention,
then 4, 6 and 12 months. Participants will also
complete a healthcare utilisation checklist and proxy
performance status which will be assessed at baseline
and monthly. 240 carers will be recruited. The sample
size is 180. Multilevel mixed effects regression models
will be applied to test the effect of the intervention.
Ethics: Ethics approval has been gained from Curtin
University and the participating sites.
Dissemination: Results will be reported in
international peer-reviewed journals.
Trial registration number: Australian and New
Zealand Clinical Trials Registration (ACTRN)
12612001147875.
INTRODUCTION
High-grade glioma (HGG) is a term used
to encompass grade III anaplastic astrocyto-
mas, oligodendrogliomas and glioblastoma
(grade IV). This is a rapidly terminal, pro-
gressive and debilitating group of diseases
which deprives patients of function, cogni-
tion and personality, making this a highly
distressing disease for patients, families and
carers.1 Seventeen hundred new cases of
malignant brain cancer are diagnosed each
year in Australia.2 In a retrospective review
of survival in over 10 000 patients with glio-
blastoma diagnosed over a decade (1998–
2008), the median survival was 12.6 months
with a 2-year survival rate of 15%.3 With the
incorporation of temozolomide chemother-
apy into standard care for HGG, the
current median survival is expected to be
in the region of 15 months4 and second-
line treatment may have extended this
further.5
Strengths and limitations of this study
▪ This study uses a randomised controlled trial
design to test an intervention for family care-
givers of patients with high-grade glioma.
▪ This study is trialling an intervention to address
the high levels of distress demonstrated in carers
in our pilot work, which was higher than that of
the patient.
▪ The cost-effectiveness of this intervention will
also be determined.
▪ No attention control.
▪ Heterogeneous usual care received in both
groups, although this mirrors usual clinical
practice.
Halkett GKB, et al. BMJ Open 2015;5:e009477. doi:10.1136/bmjopen-2015-009477 1
Open Access Protocol
group.bmj.com on March 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
The carers’ experience
Caring for someone with a brain tumour is unique
because of the cognitive, personality and functional
changes that occur. In addition to the general cancer-
related caregiving issues, the impact of the disease on
the patients’ ability to function leads to reduced quality
of life, increased stress and carer burden.6 The diagnosis
of a brain tumour is particularly stressful for carers
because the prognosis is dire and life expectancy short.
The cognitive changes and, in particular, personality
changes associated with HGG lead to changes in family
roles and relationships that are not regularly seen with
other cancers, and can occur shortly after the initial
diagnosis rather than solely at the end of the disease tra-
jectory. Cognitive disability or dysphasia may also render
the carer the primary communicator and medical deci-
sion maker. Furthermore, the legal inability of patients
to drive adds transport to the carer’s responsibilities.7
Carers of people with HGG also need to accommodate
the neurological changes that characterise the disease,
such as paralysis, seizures, vision and hearing loss. It is
therefore unsurprising that these carers report increased
stress and distress levels7a and decreased quality of life
compared with carers of patients with cancers with a
good prognosis.8 Carers of patients with primary malig-
nant glioma report inadequate preparation and a lack of
individualised support and information.9
A diagnosis of cancer brings changes in roles and
care-related tasks. In the setting of HGG, these
changes can occur rapidly after the diagnosis com-
pared with other cancers where the change may be
more related to a phase of aggressive treatment or the
terminal phase. These care-related tasks may also
incorporate new caring activities that require some new
learning for the carer. Carers of patients with advanced
cancer experience substantial loss in their self-identity,
give up signiﬁcant parts of their lives including work,
and may move house to care.10 They are also often
unable to take time out for self-care or to accept help
in caring. Carers of people who die soon after diagno-
sis experience greater levels of depression than those
caring for people with a long illness trajectory, and in
some cases, these levels of depression are clinically
signiﬁcant and directly related to the patients
symptomatology.11
Healthcare costs of HGG
Not only is HGG distressing for patients and carers, it
also carries a high social and ﬁnancial burden. In an
Australian economic review of the cost of cancer pub-
lished in 2007, ‘brain cancer’ was one of the most
expensive cancers with the estimated lifetime cost of
brain cancer per person being estimated at $1.9
million. In a country with universal healthcare, the
federal government and society cover around half this
cost.12 Interventions which may reduce costs to the
healthcare system, patients diagnosed with HGG and
their carers are clearly needed. The current healthcare
system has substantive gaps in strategies which support
carers uniformly and over time, in context of the illness
of the person they are caring for, matched to their
needs, and when they are providing care in their home.
In times of crisis, carers are often left with emergency
department visits as their only avenue of support, which
are unable to meet these needs. It is a common occur-
rence that the patients’ length of stay in hospital is pro-
longed when their carers are experiencing carer fatigue
and stress.
Interventions for carers
There is currently a directive from the WHO and recent
guidelines on the psychosocial support of carers that
adequate psychological support should be provided to
carers of patients receiving palliative care.13 14
Appropriate education and support interventions need
to be trialled and implemented into practice to assist in
meeting the needs of carers and reducing their psycho-
logical distress.
Psychosocial interventions for carers in a range of
situations have been developed with various aims includ-
ing improving carer understanding and ability to care,
self-efﬁcacy, quality of life, stress reduction, and commu-
nication and relationships in the family.15 Previous inter-
ventions include information provision and education,
relaxation, counselling and support, and self-care.15–18
Hudson and colleagues have shown that psychoeduca-
tional support increases carers’ preparedness to care,
carer competence, sense of reward and sense of having
their needs met.19
Support for psychoeducational interventions speciﬁc-
ally for HGG carers has emerged from the Netherlands
in a recent small randomised controlled trial (RCT;
n=56 patient-carer dyads).20 Carers in the intervention
group attended six sessions with a psychologist who pro-
vided psychoeducation on disease-speciﬁc symptoms,
strategies for problem solving and cognitive behavioural
therapy to increase coping with the caring role.
Compared with standard care, the intervention helped
carers maintain stable mental functioning and improved
their sense of mastery.20 Further large-scale research
needs to be conducted to determine the effect of sup-
porting carers from the time of diagnosis of HGG until
bereavement.
Hudson and Aranda21 showed that support pro-
grammes for family carers of patients with terminal
illness can improve carer preparedness, competence,
psychological well-being and reduce unmet needs, but
concluded more rigorous studies are needed. A
meta-analysis of interventions with carers of patients
with cancer concluded that small-to-medium effect sizes
were appropriate for measuring psychological out-
comes.15 Further research using adequately powered
RCTs is needed to establish: when support should be
provided, how to assess carer needs, and how to provide
effective psychosocial support to carers.15–18
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Preliminary data
Thus far several members of this team have carried out
two investigations into the experience and needs of
patients with HGG and their carers. The ﬁrst was a quali-
tative study of the needs of patients with HGG and their
carers in which semistructured interviews with 19 patients
and 21 carers were carried out.7 22 23 Carers described
the period immediately following diagnosis of HGG as a
time of rapid change during which they had to renegoti-
ate roles and relationships and learn to be a carer in a
short period of time. They described a steep learning
curve where they struggled with caring for partners with
major disabilities such as hemiparesis, learning how to
manage personal care and medications, dealing with sei-
zures and participating in treatment decision-making.7 22
The second investigation, a multicentre (Western
Australia (WA) and New South Wales (NSW)) quantita-
tive study, examined the experiences of 113 patient-carer
dyads at three time points during the disease trajectory:
during chemoradiotherapy, and 3 and 6 months later.
Results from the baseline data have been published.7a 24
Carers reported signiﬁcantly higher levels of distress
than patients at baseline and 3 months and between a
1/4 and 1/3 of carers fell into the highest distress cat-
egory at each time point. Almost 50% of carers reported
high or moderate unmet supportive care needs. Their
most important needs pertained to gaining information
(eg, side effects, prognosis), coping and addressing psy-
chological concerns, practical needs, coordination of
care and adjusting to personality and behavioural issues
of the patients.
Intervention development
This intervention was developed using the UK Medical
Research Council framework for developing and evaluat-
ing complex interventions.25 The content of the inter-
vention was based on preliminary data,7 22 identiﬁcation
of key components from other studies and a conceptual
model to explain individual responses to caregiving.26
Hudson26 proposed a conceptual model and identiﬁed
important key variables in identifying and understanding
the individual response and experience of carers in the
setting of palliative care, namely preparedness to care,
sense of control, competence, self-efﬁcacy, anxiety,
depression and distress, social support, information, a
sense of reward, meaningfulness, positive emotions, opti-
mism, respite and relationship with the patient. Our
intervention aims to cover all these areas. The following
stakeholders participated in development of the
resource: medical oncologists, neurosurgeons, radiation
oncologists, palliative care physicians, psychiatrists, psy-
chologists, social workers, occupational therapists, nurses
(neuro-oncology cancer nurse coordinator, palliative
care nurse coordinator, seizure education nurse, dia-
betes education nurse, and continence advisor), experi-
enced representatives from Carers WA and the
Cooperative Trials Group for Neuro-Oncology
(COGNO), as well as consumer representatives.
Feasibility pilot study
The intervention has been piloted with 10 carers in WA.
The pilot enabled the trained neuro-oncology research
nurse to trial intervention delivery, all components of
the intervention and assessments used and receive feed-
back from carers. Additional content was added to the
resource following this piloting. Feedback from partici-
pants was overwhelmingly positive regarding the value
and structure of the intervention.
AIMS
This RCT aims to enable carers of patients with HGG to
sustain their caregiving role and minimise their distress.
The primary objective is to assess the efﬁcacy of a sup-
portive educational intervention for carers in improving
the primary carer preparedness to care and reducing
their distress.
PRIMARY HYPOTHESIS
Carers who receive the intervention will feel more pre-
pared for caring and experience less psychological dis-
tress as the patient’s disease progresses.
SECONDARY HYPOTHESES
1. Carers who receive the intervention will have fewer
unmet needs than those in the usual care group.
2. Carers who receive the intervention will have a better
quality of life than those in the usual care group.
3. This intervention will reduce patient healthcare
resource utilisation and, by doing so, will reduce
costs.
METHODS
Trial design
A multicentre, non-blinded prospective, phase III RCT.
The CONSORT guidelines27 are being followed for
recruitment and monitoring of response rates and with-
drawals. On completion of consent and baseline survey,
the carer is randomised to the intervention or control
group. The trial schema is shown in ﬁgure 1.
Settings
Recruitment is occurring at two oncology providers in
WA. Additional funding for sites in Victoria and NSW is
being sought.
Sample recruitment
A consecutive sample of adult primary carers of patients
with HGG is being recruited. Eligibility criteria:
1. Primary carer of patient with HGG who is currently
undergoing active treatment with chemotherapy,
radiotherapy or combined chemoradiotherapy and
within 2 months of initial diagnosis.
2. Patient is currently attending the neurosurgical,
medical or radiation oncology outpatient depart-
ments of a participating site.
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3. Age 18 years and above.
4. Sufﬁcient understanding of verbal and written
English language.
5. Primary carer has no mental, cognitive or functional
disability.
6. Willing and able to comply with study requirements,
timing and nature of required assessments.
7. No familial, sociological or geographical condition
potentially hampering compliance with the study
protocol, including alcohol dependence or drug
abuse.
8. No severe intercurrent medical or psychotic illness
that in opinion of the investigator would jeopardise
the ability to participate in the study intervention or
assessments.
Recruitment
Depending on site, screening for eligibility is carried out
by the medical oncologists, radiation oncologist, neuro-
surgeons, or neuro-oncology cancer nurse coordinator,
at the start of treatment for HGG. As carers often attend
the medical appointments, the clinicians are able to
brieﬂy discuss the study with patients and their carers
and request their permission to provide their contact
details to the research assistant. After potential partici-
pants are identiﬁed, the research assistant invites the
carer and patients to participate and provides informa-
tion regarding the study. Participants are given time to
consider the study before written informed consent and
the baseline questionnaires are obtained. The ﬁrst par-
ticipant of the study was enrolled in February 2014.
At the beginning of September 2015 50 participants had
been randomised for the study in WA.
Randomisation
Participants are registered when they complete informed
consent and the baseline questionnaire and then subse-
quently randomised. Intervention delivery is planned to
start within 28 days of randomisation. Participants are
stratiﬁed by the patient’s European Cooperative
Oncology Group (ECOG) score (0–1 or ≥=2) and par-
ticipating site to achieve an even distribution to each
study arm of cases of differing severity and from the dif-
ferent sites.
Block randomisation to treatment arm within each
strata is carried out using a computer-generated random-
isation table. Allocation to the treatment arms is carried
out by the principal investigator rather than the nurse
delivering the intervention. The treatment site is not
informed which arm patients are randomised to, but
blinding is not practical due to the nature of the
intervention.
Intervention content
There are four main aspects to this intervention: initial
telephone assessment of carer needs; a personalised
tabbed resource ﬁle; home visit and ongoing telephone
support (ﬁgure 2). All aspects of the intervention are
documented and standardised in an evidence-based
study manual which also contains resources for the inter-
vention nurses.
Intervention nurse training and quality assurance
In WA, training has been provided by the multidisciplin-
ary team involved in developing the intervention and
Carers WA. The WA intervention nurse and a CI experi-
enced in communication skills training will travel to
train intervention nurses at other sites. The training will
include communication skills training, role plays and
familiarisation with each component of the intervention.
Intervention nurses at other sites will individualise local
resource information in order to integrate with current
practice models, but all sites will utilise the same educa-
tional information and framework. Each intervention
nurse will pilot delivery of the intervention to ﬁve carers.
Tape recordings of intervention delivery will be assessed
for adherence to the protocol for the piloting and a
random 5% of carer home visits.
Usual care
The control arm will receive ‘usual care’ which may
include currently available educational resources which
generally focused on the patient rather than carers, and
are not speciﬁc to the role of caring for patients with
HGG. The patient may also have access to a cancer-
speciﬁc care coordinator and/or oncology nursing staff.
Medical or nursing staff will provide reactive referrals
for both groups as per usual practice where needs are
identiﬁed within the course of routine clinical care,
including referrals to a psychologist, seizure education
nurse, palliative care and other appropriate available
services.
Full standard medical care and supportive manage-
ment as clinically indicated is allowable on both arms.
Measures
Primary outcome measures are: carer preparedness mea-
sured by the Preparedness for Caregiving Scale28 and
Figure 1 Trail schema (HGG,
high-grade glioma).
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carer distress measured by the Distress Thermometer
(DT).29 30 Secondary outcome measures are carer
anxiety and depression measured using the Hospital
Anxiety and Depression Scale (HADS),31 carer quality of
life measured by the Caregiver Quality of Life Index—
Cancer,32 carer competence measured by the Carer
Competence Scale,33 carer supportive care needs measured
by the ‘Partner and Caregivers Supportive Care Needs
Scale’34 and ‘Brain Tumour Speciﬁc Supportive Carer
Needs for Carers Survey’35 and health economic cost-
consequences measured using a checklist of services used.
All measures pertain to the carer except the ECOG
performance status36 and healthcare utility assessments
which involve information about the patient. The
patient will also be asked to complete the EuroQoL-5D
(EQ-5D)37 at baseline. Figure 3 describes the measures
being used and when each assessment is collected.
Data collection time points
The main collection points are baseline and 8 weeks, 4,
6 and 12 months. Data collection is completed by the
research assistant for both groups. Patient performance
status and health economic measures are collected
monthly via phone calls. Participants are prompted by
up to three phone calls for each time point. Participants
who withdraw are followed up for patient survival and a
bereavement call will be made.
Ethical considerations
The current version of the protocol at Sir Charles Gairdner
Hospital (SCGH) is V.1.3. All of the Human Research
Ethics Committees (HREC) conduct random independent
audit, and this study may be audited under these auspices.
Protocol modiﬁcations will be submitted for ethical
approval as an amendment to all committees and dissemi-
nated to investigators. This study was registered with the
Australian and New Zealand Clinical Trials Registration:
ACTRN12612001147875 on 30 October 2012.
The purpose of the study will be clearly explained to
participants verbally and in writing. Informed consent
will be gained from both the participating carer and the
patient. Participation is voluntary and study withdrawal is
possible at any time. In order to minimise the risk of dis-
tress, it will be made clear to patients that participation
(or non-participation) will not inﬂuence potential
future availability of medical treatment. Carer and
patient conﬁdentiality will be protected under standards
recognised by Australian Good Clinical Practice (GCP)
guidelines and applicable Privacy Acts and Regulations.
All data generated in this study will remain conﬁdential.
All information will be stored securely at Curtin
Figure 2 Care-IS intervention content.
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University and will only be available to people directly
involved with the study and who have signed a
Conﬁdentiality Agreement.
As this study will require reﬂection by carers on their
care needs and the deterioration of their relative, there is
a potential for increased distress of participants.
Psychological distress will be assessed at each time point. If
a research assistant identiﬁes a carer as having high levels
of anxiety or depression (HADS score of >15 for either
anxiety or depression) the patient’s treating clinician will
be notiﬁed and referrals will be made for supportive care
in the usual, pre-existing referral pathways. Any serious
adverse events considered related to the intervention will
be reported as required by regulatory authorities.
Study governance
The steering committee for this study includes the fol-
lowing authors: GKBH, AKN, EAL, LM, JLP, TS, RM and
PH. The steering committee will be responsible for
study design, start, and evaluating and reporting of the
results of the trial. The steering committee will meet at
least every 6 months throughout the study.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The trial is sponsored by Curtin University and the
University of WA. The lead author can be contacted at:
g.halkett@curtin.edu.au. Trial investigators will permit
authorised third parties access to data relating to
Figure 3 Measures and reliability.
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participants. This will include access for monitoring and
Ethics Committee review. The funders and sponsors will
not be involved in data analysis or reporting; however,
they will be provided with copies of any publications
arising from the study.
Sample size and power calculation
Two co-primary end points will be used: carer prepared-
ness and carer distress at 4 months. Using a 5% signiﬁ-
cance level, two-tailed testing of differences between
two independent groups (usual care and intervention),
a sample of 64 patients per group (128 total), has 80%
power to detect group differences of 0.5 SDs (moderate
effect size; considered clinically signiﬁcant) for carer
preparedness.38 This sample size is based on means of
20 and 22.5 (SD=5, range 0–32) for carer prepared-
ness.19 Having previously used the DT with carers,7a we
propose that we will be able to reduce the number of
carers with high levels of distress from the expected
33% in the control group to 13% (20% difference) in
the intervention group at 4 months post baseline. To
detect this difference between groups (with 5% signiﬁ-
cance and two-tailed testing), we will need a sample size
of 78 carers per arm (156 in total). Thus, a sample size
of 156 at post intervention testing will be sufﬁcient for
both primary end points.
We have considered whether there may be site-level
differences. Our previous work using the DT showed
that at baseline and 3 months, intraclass correlation
coefﬁcient values were 0, that is, no evidence of site-level
clustering was found. Hence, it is not necessary to
account for clustering design effects.
Based on our previous studies where 98% of eligible
carers were approached, with a 67% consent rate, we
estimate 35% attrition from baseline to 4 months post-
diagnosis, implying that 240 carers are needed at base-
line (manuscript under review). To achieve 240 carers
at baseline, 364 will need to be identiﬁed as eligible
and 356 to be approached. The ﬁnal sample size of
240 patients at baseline (with attrition, 156 at 4
months), as calculated using the two primary outcome
measures, allows us to test for effect sizes of the same
magnitude for the secondary outcomes at 3 months.
Assuming a 20% drop-out between the 3-month and
6-month follow-up based on our previous studies, the
sample size will be approximately 62 per group. This
sample size has power of 80% to detect an effect size
of 0.51 for preparedness and a difference of 23% on
the DT—effects of similar magnitude to those at
4 months.
Data management and analysis
Data management and storage will occur at Curtin
University. Full details about data management for this
study can be found in the SCGH ethics protocol. A data
management committee is not needed for this study. All
data entry will be subject to a 10% check, and analysis
will be discussed and guided by the steering committee.
No interim analysis is planned. The ﬁnal trial data set
will be available to the steering committee and the full
protocol and participant-level data set will be available
through the principal investigator.
Intervention effects will be assessed by conducting
linear and logistic random effects models incorporating
a time by group interaction or latent growth curve mod-
elling to determine whether trends across the three
data points within the course of the patients’ treatment
differ between the carer groups.39 The models will
adjust for confounders and effect modiﬁers as neces-
sary. Models will be ﬁtted for primary and secondary
outcome measures. Model assumptions, such as normal-
ity assumptions, will be tested and appropriate methods
used to ensure assumptions are met. Missing data for
speciﬁc time points and from loss to follow-up will be
dealt with through multivariate multiple imputation or
full information maximum likelihood methods as
appropriate.
Cost-consequence analysis
The following costs will be calculated:
1. Carer-related costs related to brain tumour-speciﬁc
supportive care needs—will be costed based on infor-
mation from both data collected in our pilot study
and costs recorded using the checklist of services
completed by carers in the intervention and control
groups.
2. Patient healthcare utilisation costs—healthcare system
costs will be calculated for patient admissions and
length of stay in hospital using the Diagnostic
Related Groups (DRG) and the relevant national efﬁ-
cient price by allocating the DRG that matches
closest to the patient admission information. Cost of
emergency department presentations will be based
on allocation of the closest Urgency Related Group.
Hospice and residential care costs will be derived
from Australian Institute of Health and Welfare data.
The costs and outcomes of delivering the intervention
will be compared using cost-outcomes (cost-
consequence) analysis, a variant of cost-effectiveness
analysis in which components of incremental costs and
outcomes are computed and listed without any attempt
to aggregate these results into a formal ratio.
Cost-outcomes analysis provides a more comprehensive
presentation of information than other types of eco-
nomic evaluation and is appropriate for complex
interventions that generate outcomes that cannot mean-
ingfully be expressed using a single metric such as those
in this study.40 The consequences (outcomes measures
as described above) and net costs (cost of the interven-
tion—any cost savings produced by the intervention) will
be tabulated to allow an analysis of the cost per net
change in the outcome individually and aggregated by
type for the outcomes detailed below:
1. Carer-related outcomes: (1) increase preparedness for
caring; (2) reduction in carer distress; (3) increase in
carer quality of life; (4) reduction in carers’ brain
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tumour-speciﬁc supportive care needs; (5) increase
in carer competence.
2. Patient healthcare utilisation outcomes: (1) reduction in
patient admissions and length of stay in hospital; (2)
reduction in hospice and residential care requests;
and (3) reduction in the number of presentations to
emergency departments and unplanned admissions
from outpatient clinics.
Publications
A writing group will be formed by the steering commit-
tee and all authors will meet ICMJE criteria for author-
ship. Professional writers will not be used for
publications arising from this study. Results will be disse-
minated in the peer-reviewed literature and by presenta-
tion at national and international scientiﬁc meetings.
Results will be communicated to the consumer advisory
group and through study funders and collaborators
including Cancer Council WA, Carers WA, and the WA
Cancer and Palliative Care Network.
DISCUSSION
HGG is a rapidly progressive, terminal disease which
also deprives patients of function, cognition and person-
ality. These unique characteristics mean HGG is a highly
distressing disease for carers, and an expensive disease
for the wider community. Patients are frequently admit-
ted to hospital or alternative care due to carer fatigue or
lack of preparation for care at home. Australian data
conﬁrm both the psychological and ﬁnancial costs of
HGG.12
This study will provide evidence on whether using a
preparedness for caring intervention reduces carer dis-
tress, improves carer outcomes and reduces patient
healthcare resource utilisation and overall costs. If this
research study has positive outcomes and is cost-
effective, this intervention could be feasibly implemen-
ted in routine clinical practice. This randomised phase
III trial is designed to provide evidence for changes in
practice and policy in Australia and elsewhere. If we can
demonstrate positive carer outcomes and cost-neutrality
or even cost-savings, we would be in an ideal position to
advocate for routine provision of similar services.
Furthermore, if successful, the intervention model may
be relevant to test in carers of patients with other rapidly
progressing cancers or neurodegenerative diseases.
CONCLUSION
This is the ﬁrst study internationally to systematically test
a nurse-led home intervention to address carers levels of
distress and lack of preparedness to care for their rela-
tive following a diagnosis of HGG. The proposed inter-
vention package consists of an initial phone assessment,
nurse-led home visit, tailored resource manual and
ongoing telephone contact. We anticipate that this inter-
vention will reduce carer distress and improve their level
of preparedness to care for the patient with HGG.
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